| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_dc170ff7b9b6d9a780b852b8484e5a69
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_4d0054712f33521c521df8c30997e35d |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-2875 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-395 |
| filingDate |
2006-12-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_37bc8a542863960184a98e736d05a8bc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_753fcccc90de97dac37755a87031f38d |
| publicationDate |
2007-08-02-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-2007178087-A1 |
| titleOfInvention |
Method for Treating Immune Dysfunction by Regulation of CD40 Ligand Expression |
| abstract |
Techniques for treating immune dysfunction in a patient by regulation of CD40 Ligand (CD40L) expression are provided. For example, one technique includes suppressing TFE3 and/or TFEB in the patient to thereby suppress CD40L expression in the patient. In addition, the technique may include administering a TFE3 inhibitor and/or a TFEB inhibitor for suppressing TFE3 and/or TFEB, respectively, in the patient. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2010135695-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2012095079-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/WO-2011082281-A3
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-8895527-B2 |
| priorityDate |
2005-12-15-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |